Combination therapy for ischemic stroke: Novel approaches to lengthen therapeutic window of tissue plasminogen activator
Authors:
Open Access
- 1 January 2018
- journal article
- review article
- Published by Medknow in Brain Circulation
- Vol. 4 (3) , 99-108
Abstract
Tissue plasminogen activator (tPA) thrombolysis continues to be the gold standard therapy for ischemic stroke. Due to the time-limited treatment window, within 4.5 h of stroke onset, and a variety of potentially deadly complications related to delayed administration, particularly hemorrhagic transformation (HT), clinical use of tPA is limited. Combination therapies with other interventions, drug or nondrug, have been hypothesized as a logical approach to enhancing tPA effectiveness. Here, we discuss various potential pharmacological and nondrug treatments to minimize adverse effects, primarily HT, associated with delayed tPA administration. Pharmacological interventions include many that support the integrity of the blood–brain barrier (i.e., atorvastatin, batimastat, candesartan, cilostazol, fasudil, and minocycline), promote vascularization and preserve cerebrovasculature (i.e., coumarin derivative IMM-H004 and granulocyte-colony stimulating factor), employing other mechanisms of action (i.e., oxygen transporters and ascorbic acid). Nondrug treatments are comprised of stem cell transplantation and gas therapies with multi-faceted approaches. Combination therapy with tPA and the aforementioned treatments demonstrated promise for mitigating the adverse complications associated with delayed tPA treatment and rescuing stroke-induced behavioral deficits. Therefore, the conjunctive therapy method is a novel therapeutic approach that can attempt to minimize the limitations of tPA treatment and possibly increase the therapeutic window for ischemic stroke treatment.Keywords
This publication has 68 references indexed in Scilit:
- Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising MinocyclineStroke Research and Treatment, 2013
- RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational ResearchTranslational Stroke Research, 2012
- Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic StrokeStroke, 2011
- Bone marrow stem cell mobilization in stroke: a ‘bonehead’ may be good after all!Leukemia, 2011
- Phosphodiesterase-III Inhibitor Prevents Hemorrhagic Transformation Induced by Focal Cerebral Ischemia in Mice Treated with tPAPLOS ONE, 2010
- Recombinant Human Erythropoietin in the Treatment of Acute Ischemic StrokeStroke, 2009
- Atorvastatin Extends the Therapeutic Window for tPA to 6 h after the Onset of Embolic Stroke in RatsJournal of Cerebral Blood Flow & Metabolism, 2009
- Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1Journal of Neuroscience, 2008
- Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic strokeNature Medicine, 2008
- Hypoxia Disrupts the Barrier Function of Neural Blood Vessels through Changes in the Expression of Claudin-5 in Endothelial CellsThe American Journal of Pathology, 2007